OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).

OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 11.8 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Novel Approaches to Glioblastoma

Submission Deadline: November 30, 2020 (Open) Submit Now

Guest Editor

Divya Mella, MD

Attending Neuro-Oncologist, Baylor Scott and White, Dallas, TX-USA

Website | E-Mail

Research Interests: Neuro-Oncology; Brain Tumors; Neuropathology; Neuroimaging


Open Access Review

Minimally Invasive Treatments for Glioblastoma: A Review of Current and Emerging Surgical Technologies

Received: 22 February 2022;  Published: 03 March 2023;  doi: 10.21926/obm.neurobiol.2301160


Glioblastoma (GBM) is malignant, primary intracranial neoplasm associated with poor outcomes. Maximal, safe cytoreduction remains an important component of effective treatment for patients with this disease; however, some patients are not candidates for resection due to comorbid status, tumor location, or other factors. In this review, we [...]
Open Access Review

Examining the Role of Specialized DNA Polymerases in the Development of Temozolomide Resistance in Glioblastoma Multiforme

Received: 09 February 2021;  Published: 18 May 2021;  doi: 10.21926/obm.neurobiol.2102096


Glioblastoma multiforme (GBM) is an extremely malignant type of primary brain tumor that exhibits a high mortality rate. Current standard therapy involves surgery followed by radiation and treatment with the DNA-alkylating agent, temozolomide (TMZ). While TMZ treatment can extend post-operative survival, most patients develop resis [...]
Open Access Review

Light-Activated Local Drug Delivery From Hydrogels: Potential for GBM Treatment

Received: 15 December 2020;  Published: 23 March 2021;  doi: 10.21926/obm.neurobiol.2101090


Following post-operative treatment, the vast majority of GBMs recur, usually within 2 cm of the tumor resection margin. Since these tumors seldom metastasize outside the CNS, improved localized therapies should prove beneficial. Drug delivery systems (DDS) that allow control over drug release by an externally applied energy, such as light [...]